Finasteride reduces the risk of incident clinical benign prostatic hyperplasia.

[1]  John T. Wei,et al.  Update on AUA guideline on the management of benign prostatic hyperplasia. , 2011, The Journal of urology.

[2]  S. Kaplan,et al.  Association of nocturia and mortality: results from the Third National Health and Nutrition Examination Survey. , 2011, The Journal of urology.

[3]  T. Wilt,et al.  5‐α‐Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review , 2010, BJU international.

[4]  E. Barrett-Connor,et al.  Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study. , 2010, The Journal of urology.

[5]  D. Tindall,et al.  Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[6]  John T. Wei,et al.  Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. , 2009, The Journal of urology.

[7]  J. K. Parsons,et al.  Lower urinary tract symptoms increase the risk of falls in older men , 2009, BJU international.

[8]  T. Wilt,et al.  Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. , 2009, The Journal of urology.

[9]  I. Thompson,et al.  Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. , 2008, American journal of epidemiology.

[10]  E. Barrett-Connor,et al.  Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. , 2008, Urology.

[11]  I. Thompson,et al.  Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. , 2008, American journal of epidemiology.

[12]  I. Thompson,et al.  THE PROSTATE CANCER PREVENTION TRIAL AND THE FUTURE OF CHEMOPREVENTION , 2008, BJU international.

[13]  S. King,et al.  Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required , 2008, Circulation.

[14]  Christina Wang,et al.  The Effect of 5α-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men , 2007 .

[15]  I. Thompson,et al.  Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. , 2007, The Journal of urology.

[16]  P. Walsh.  Re: The Prostate Cancer Prevention Trial: design, biases and interpretation of study results. P. J. Goodman, I. M. Thompson, Jr., C. M. Tangen, J. J. Crowley, L. G. Ford and C. A. Coltman, Jr., J Urol, 175: 2234-2242, 2006. , 2006, The Journal of urology.

[17]  John T. Wei,et al.  Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. , 2006, Archives of internal medicine.

[18]  T. Wilt,et al.  Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. , 2006, Urology.

[19]  L. Ferrucci,et al.  Metabolic factors associated with benign prostatic hyperplasia. , 2006, The Journal of clinical endocrinology and metabolism.

[20]  J. Crowley,et al.  The prostate cancer prevention trial: design, biases and interpretation of study results. , 2006, The Journal of urology.

[21]  Ruth Etzioni,et al.  Associations of demographic and lifestyle characteristics with prostate‐specific antigen (PSA) concentration and rate of PSA increase , 2006, Cancer.

[22]  G. Joyce,et al.  Economic costs of benign prostatic hyperplasia in the private sector. , 2005, The Journal of urology.

[23]  G. Steineck,et al.  Self‐assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract , 2005, BJU international.

[24]  John T. Wei,et al.  Urologic diseases in America project: benign prostatic hyperplasia. , 2005, The Journal of urology.

[25]  D. Tindall,et al.  Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. , 2004, The Journal of urology.

[26]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[27]  I. Thompson,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[28]  B. Psaty,et al.  Cost-minimization and the number needed to treat in uncomplicated hypertension. , 1998, American journal of hypertension.

[29]  T. Wilt,et al.  5-a-Reductase inhibitors for prostate cancer chemoprevention: An updated Cochrane systematic review (BJU International (2010) 106:10 (1444-1451)) , 2011 .

[30]  F. Zacharias.  Beta blockers in hypertension. , 1973, Bruxelles medical.